This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 227)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02477826
Recruitment Status : Active, not recruiting
First Posted : June 23, 2015
Last Update Posted : January 8, 2024
Ono Pharmaceutical Co. Ltd
Information provided by (Responsible Party):
Bristol-Myers Squibb

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : August 29, 2024
Estimated Study Completion Date : August 30, 2024
Publications automatically indexed to this study by Identifier (NCT Number):